Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension.

Anan F, Takahashi N, Ooie T, Yufu K, Hara M, Nakagawa M, Yonemochi H, Saikawa T, Yoshimatsu H.

Eur J Clin Pharmacol. 2005 Jul;61(5-6):353-9. Epub 2005 May 26.

PMID:
15918057
2.
3.

Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.

Ferri C, Croce G, Desideri G.

Adv Ther. 2008 Apr;25(4):300-20. doi: 10.1007/s12325-008-0042-x. Review.

PMID:
18449492
4.
5.

Clinical experience with angiotensin receptor blockers with particular reference to valsartan.

Chrysant SG, Chrysant GS.

J Clin Hypertens (Greenwich). 2004 Aug;6(8):445-51. Review.

6.

Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both.

Verdecchia P, Angeli F.

Clin Ther. 2004 Apr;26(4):460-72. Review.

PMID:
15189744
7.

Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension.

Matheson AJ, Cheer SM, Goa KL.

Drugs. 2001;61(8):1211-29. Review.

PMID:
11465878
8.

Valsartan in chronic heart failure.

Ripley TL.

Ann Pharmacother. 2005 Mar;39(3):460-9. Epub 2005 Feb 1. Review.

PMID:
15687480
9.

[Cardiac hypertrophy and arterial compliance after antihypertensive treatment].

Asmar RG, Pannier BM, London GM, Safar ME.

Arch Mal Coeur Vaiss. 1991 Dec;84 Spec No 4:79-83. Review. French.

PMID:
1838923
10.

Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT).

Chrysant SG.

Expert Rev Cardiovasc Ther. 2003 Sep;1(3):335-43. Review.

PMID:
15030262
11.

Perindopril: an updated review of its use in hypertension.

Hurst M, Jarvis B.

Drugs. 2001;61(6):867-96. Review.

PMID:
11398915
12.

Perindopril: the reasonable choice in patients with coronary artery disease.

Cockcroft JR.

Int J Clin Pract. 2005 May;59(5):600-4. Review.

PMID:
15857358
13.

Effects of perindopril on cardiovascular remodeling.

McVeigh GE.

Am J Cardiol. 2001 Oct 4;88(7A):28i-35i. Review.

PMID:
11591358
14.

Angiotensin converting enzyme inhibition, pulse wave velocity and ambulatory blood pressure measurements in essential hypertension.

Santoni JP, Asmar R, Safar ME.

Clin Exp Hypertens A. 1989;11 Suppl 2:535-44. Review.

PMID:
2691127
15.

Cardiac effects of combination therapy in hypertension.

Messerli FH, Chander K.

J Cardiovasc Pharmacol. 2000;35 Suppl 3:S17-22. Review.

PMID:
10854047
16.

Left ventricular hypertrophy and angiotensin II receptor blocking agents.

Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Hirohashi K.

Curr Med Chem Cardiovasc Hematol Agents. 2005 Jan;3(1):61-7. Review.

PMID:
15638745
17.

Efficacy of perindopril in the treatment of systemic hypertension.

Oparil S.

Am J Cardiol. 2001 Oct 4;88(7A):3i-12i. Review.

PMID:
11591355
18.

Effects of combination therapy on the heart.

Messerli FH, Michalewicz L.

J Hum Hypertens. 1997 Jan;11(1):29-33. Review.

PMID:
9111154
19.

[Hypertrophy of left ventricular myocardium as modifiable risk factor: novel possibilities of correction].

Bulkina OS, Talitskiń≠ KA, Karpov IuA.

Kardiologiia. 2006;46(3):68-72. Review. Russian.

PMID:
16710260
20.

Therapeutic potential of angiotensin receptor blockers in hypertension.

Cheung BM.

Expert Opin Investig Drugs. 2006 Jun;15(6):625-35. Review.

PMID:
16732715

Supplemental Content

Support Center